

# Time matters: The potential of rapid-acting antidepressants in treatment-resistant depression

Industry session financially supported by GH Research during the 38<sup>th</sup> ECNP Congress.

🕒 **Monday 13 October 2025**  
08:40 – 10:00  
📍 **Elicium 2**

## Programme Outline

Join us as we discuss the potential of rapid-acting antidepressants in treatment-resistant depression (TRD). This Satellite Symposium will explore current clinical practice treatment pathways, mechanisms of psychedelic molecules including mebufotenin, and recent clinical data on the use of rapid-acting antidepressants in TRD.

**Session ID:**

ISS07

**Session type:**

Industry Satellite Symposium

## Faculty



**CHAIRPERSON**

**Michael E. Thase**


Professor of Psychiatry,  
Department of Psychiatry of the  
Perelman School of Medicine,  
University of Pennsylvania,  
Corporal Michael J. Crescenz  
Veterans Affairs Medical Center,  
Philadelphia, U.S.A.



**SPEAKER**

**Lisa Harding**

Assistant Clinical Professor,  
Yale Department of Psychiatry.  
Medical Director,  
Mood Institute,  
Connecticut, U.S.A.



**SPEAKER**

**Johannes G. Ramaekers**

Professor of Psychopharmacology  
and Behavioural Toxicology,  
Faculty of Psychology and  
Neuroscience,  
Maastricht University,  
Netherlands



**SPEAKER**

**Wiesław J. Cubała**

Professor of Psychiatry,  
Department of Psychiatry,  
Medical University of Gdańsk,  
Poland



**Scan For More  
Information**